198 related articles for article (PubMed ID: 27333593)
1. Population PK-PD analyses of CD25 occupancy, CD56
Diao L; Hang Y; Othman AA; Mehta D; Amaravadi L; Nestorov I; Tran JQ
Br J Clin Pharmacol; 2016 Nov; 82(5):1333-1342. PubMed ID: 27333593
[TBL] [Abstract][Full Text] [Related]
2. Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.
Minocha M; Tran JQ; Sheridan JP; Othman AA
Clin Pharmacokinet; 2016 Jan; 55(1):121-30. PubMed ID: 26242380
[TBL] [Abstract][Full Text] [Related]
3. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.
Martin JF; Perry JS; Jakhete NR; Wang X; Bielekova B
J Immunol; 2010 Jul; 185(2):1311-20. PubMed ID: 20543101
[TBL] [Abstract][Full Text] [Related]
4. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
Sheridan JP; Zhang Y; Riester K; Tang MT; Efros L; Shi J; Harris J; Vexler V; Elkins JS
Mult Scler; 2011 Dec; 17(12):1441-8. PubMed ID: 21807759
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ
Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry.
Ranganath T; Simpson LJ; Ferreira AM; Seiler C; Vendrame E; Zhao N; Fontenot JD; Holmes S; Blish CA
Front Immunol; 2020; 11():714. PubMed ID: 32391016
[TBL] [Abstract][Full Text] [Related]
7. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Bielekova B; Catalfamo M; Reichert-Scrivner S; Packer A; Cerna M; Waldmann TA; McFarland H; Henkart PA; Martin R
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5941-6. PubMed ID: 16585503
[TBL] [Abstract][Full Text] [Related]
8. Daclizumab and its use in multiple sclerosis treatment.
Milo R; Osherov M
Drugs Today (Barc); 2017 Jan; 53(1):7-18. PubMed ID: 28387383
[TBL] [Abstract][Full Text] [Related]
9. CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
Elkins J; Sheridan J; Amaravadi L; Riester K; Selmaj K; Bielekova B; Parr E; Giovannoni G
Neurol Neuroimmunol Neuroinflamm; 2015 Apr; 2(2):e65. PubMed ID: 25635261
[TBL] [Abstract][Full Text] [Related]
10. Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis.
Preiningerova JL; Vachova M
Ther Adv Neurol Disord; 2017 Jan; 10(1):67-75. PubMed ID: 28450896
[TBL] [Abstract][Full Text] [Related]
11. Daclizumab in multiple sclerosis.
Perez-Miralles FC
Rev Neurol; 2018 Apr; 66(8):271-282. PubMed ID: 29645071
[TBL] [Abstract][Full Text] [Related]
12. Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
Zhang Y; McClellan M; Efros L; Shi D; Bielekova B; Tang MT; Vexler V; Sheridan JP
Mult Scler; 2014 Feb; 20(2):156-64. PubMed ID: 23846354
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis.
Milo R
Ther Adv Neurol Disord; 2014 Jan; 7(1):7-21. PubMed ID: 24409199
[TBL] [Abstract][Full Text] [Related]
14. Daclizumab for the treatment of multiple sclerosis.
Papadopoulou A; Derfuss T; Sprenger T
Neurodegener Dis Manag; 2017 Oct; 7(5):279-297. PubMed ID: 28849702
[TBL] [Abstract][Full Text] [Related]
15. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis.
Jiang W; Chai NR; Maric D; Bielekova B
J Immunol; 2011 Jul; 187(2):781-90. PubMed ID: 21666061
[TBL] [Abstract][Full Text] [Related]
16. Daclizumab (anti-CD25) in multiple sclerosis.
Pfender N; Martin R
Exp Neurol; 2014 Dec; 262 Pt A():44-51. PubMed ID: 24768797
[TBL] [Abstract][Full Text] [Related]
17. Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy.
Gillard GO; Saenz SA; Huss DJ; Fontenot JD
J Neuroimmunol; 2016 May; 294():41-5. PubMed ID: 27138097
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis.
Perry JS; Han S; Xu Q; Herman ML; Kennedy LB; Csako G; Bielekova B
Sci Transl Med; 2012 Aug; 4(145):145ra106. PubMed ID: 22855463
[TBL] [Abstract][Full Text] [Related]
19. Intrathecal effects of daclizumab treatment of multiple sclerosis.
Bielekova B; Richert N; Herman ML; Ohayon J; Waldmann TA; McFarland H; Martin R; Blevins G
Neurology; 2011 Nov; 77(21):1877-86. PubMed ID: 22076546
[TBL] [Abstract][Full Text] [Related]
20. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.
Locke FL; Pidala J; Storer B; Martin PJ; Pulsipher MA; Chauncey TR; Jacobsen N; Kröger N; Walker I; Light S; Shaw BE; Beato F; Laport GG; Nademanee A; Keating A; Socie G; Anasetti C
Biol Blood Marrow Transplant; 2017 Mar; 23(3):405-411. PubMed ID: 28007665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]